Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 547

1.

Modeling and antitumor studies of a modified L-penetratin peptide targeting E2F in lung cancer and prostate cancer.

Shaik T, Rather GM, Bansal N, Minko T, Garbuzenko O, Szekely Z, Abali EE, Banerjee D, Kerrigan JE, Scotto KW, Bertino JR.

Oncotarget. 2018 Sep 7;9(70):33249-33257. doi: 10.18632/oncotarget.26064. eCollection 2018 Sep 7.

2.

Activated matriptase as a target to treat breast cancer with a drug conjugate.

Rather GM, Lin SY, Lin H, Banach-Petrosky W, Hirshfield KM, Lin CY, Johnson MD, Szekely Z, Bertino JR.

Oncotarget. 2018 May 25;9(40):25983-25992. doi: 10.18632/oncotarget.25414. eCollection 2018 May 25.

3.

Exploiting methionine restriction for cancer treatment.

Chaturvedi S, Hoffman RM, Bertino JR.

Biochem Pharmacol. 2018 Aug;154:170-173. doi: 10.1016/j.bcp.2018.05.003. Epub 2018 May 4. Review.

PMID:
29733806
4.

Gamma Secretase Inhibition by BMS-906024 Enhances Efficacy of Paclitaxel in Lung Adenocarcinoma.

Morgan KM, Fischer BS, Lee FY, Shah JJ, Bertino JR, Rosenfeld J, Singh A, Khiabanian H, Pine SR.

Mol Cancer Ther. 2017 Dec;16(12):2759-2769. doi: 10.1158/1535-7163.MCT-17-0439. Epub 2017 Oct 4.

PMID:
28978720
5.

First-in-Human Clinical Trial of Oral ONC201 in Patients with Refractory Solid Tumors.

Stein MN, Bertino JR, Kaufman HL, Mayer T, Moss R, Silk A, Chan N, Malhotra J, Rodriguez L, Aisner J, Aiken RD, Haffty BG, DiPaola RS, Saunders T, Zloza A, Damare S, Beckett Y, Yu B, Najmi S, Gabel C, Dickerson S, Zheng L, El-Deiry WS, Allen JE, Stogniew M, Oster W, Mehnert JM.

Clin Cancer Res. 2017 Aug 1;23(15):4163-4169. doi: 10.1158/1078-0432.CCR-16-2658. Epub 2017 Mar 22.

6.

Small molecule inhibitors block Gas6-inducible TAM activation and tumorigenicity.

Kimani SG, Kumar S, Bansal N, Singh K, Kholodovych V, Comollo T, Peng Y, Kotenko SV, Sarafianos SG, Bertino JR, Welsh WJ, Birge RB.

Sci Rep. 2017 Mar 8;7:43908. doi: 10.1038/srep43908.

7.

NAD+ Kinase as a Therapeutic Target in Cancer.

Tedeschi PM, Bansal N, Kerrigan JE, Abali EE, Scotto KW, Bertino JR.

Clin Cancer Res. 2016 Nov 1;22(21):5189-5195. Epub 2016 Aug 31. Review.

8.

Clinical Actionability of Comprehensive Genomic Profiling for Management of Rare or Refractory Cancers.

Hirshfield KM, Tolkunov D, Zhong H, Ali SM, Stein MN, Murphy S, Vig H, Vazquez A, Glod J, Moss RA, Belyi V, Chan CS, Chen S, Goodell L, Foran D, Yelensky R, Palma NA, Sun JX, Miller VA, Stephens PJ, Ross JS, Kaufman H, Poplin E, Mehnert J, Tan AR, Bertino JR, Aisner J, DiPaola RS, Rodriguez-Rodriguez L, Ganesan S.

Oncologist. 2016 Nov;21(11):1315-1325. doi: 10.1634/theoncologist.2016-0049. Epub 2016 Aug 26.

9.

BMI-1 Targeting Interferes with Patient-Derived Tumor-Initiating Cell Survival and Tumor Growth in Prostate Cancer.

Bansal N, Bartucci M, Yusuff S, Davis S, Flaherty K, Huselid E, Patrizii M, Jones D, Cao L, Sydorenko N, Moon YC, Zhong H, Medina DJ, Kerrigan J, Stein MN, Kim IY, Davis TW, DiPaola RS, Bertino JR, Sabaawy HE.

Clin Cancer Res. 2016 Dec 15;22(24):6176-6191. doi: 10.1158/1078-0432.CCR-15-3107. Epub 2016 Jun 15.

10.

MTHFD2--a new twist?

Tedeschi PM, Scotto KW, Kerrigan J, Bertino JR.

Oncotarget. 2016 Feb 16;7(7):7368-9. doi: 10.18632/oncotarget.7147. No abstract available.

11.

Functional annotation of rare gene aberration drivers of pancreatic cancer.

Tsang YH, Dogruluk T, Tedeschi PM, Wardwell-Ozgo J, Lu H, Espitia M, Nair N, Minelli R, Chong Z, Chen F, Chang QE, Dennison JB, Dogruluk A, Li M, Ying H, Bertino JR, Gingras MC, Ittmann M, Kerrigan J, Chen K, Creighton CJ, Eterovic K, Mills GB, Scott KL.

Nat Commun. 2016 Jan 25;7:10500. doi: 10.1038/ncomms10500.

12.

Landmark Study: The Relation of Solar Radiation to Cancer Mortality in North America.

Bertino JR.

Cancer Res. 2016 Jan 15;76(2):185. doi: 10.1158/0008-5472.CAN-15-3169. No abstract available.

PMID:
26773094
Free Article
13.

Alan Sartorelli: A Personal Remembrance.

Bertino JR.

Oncologist. 2015 Dec;20(12):1457. doi: 10.1634/theoncologist.2015-r000. No abstract available.

14.

Suppression of Cytosolic NADPH Pool by Thionicotinamide Increases Oxidative Stress and Synergizes with Chemotherapy.

Tedeschi PM, Lin H, Gounder M, Kerrigan JE, Abali EE, Scotto K, Bertino JR.

Mol Pharmacol. 2015 Oct;88(4):720-7. doi: 10.1124/mol.114.096727. Epub 2015 Jul 28.

15.

Mitochondrial Methylenetetrahydrofolate Dehydrogenase (MTHFD2) Overexpression Is Associated with Tumor Cell Proliferation and Is a Novel Target for Drug Development.

Tedeschi PM, Vazquez A, Kerrigan JE, Bertino JR.

Mol Cancer Res. 2015 Oct;13(10):1361-6. doi: 10.1158/1541-7786.MCR-15-0117. Epub 2015 Jun 22.

16.

Axl receptor tyrosine kinase is up-regulated in metformin resistant prostate cancer cells.

Bansal N, Mishra PJ, Stein M, DiPaola RS, Bertino JR.

Oncotarget. 2015 Jun 20;6(17):15321-31.

17.

Quantification of folate metabolism using transient metabolic flux analysis.

Tedeschi PM, Johnson-Farley N, Lin H, Shelton LM, Ooga T, Mackay G, Van Den Broek N, Bertino JR, Vazquez A.

Cancer Metab. 2015 May 28;3:6. doi: 10.1186/s40170-015-0132-6. eCollection 2015.

18.

A sensitive liquid chromatography-mass spectrometry bioanalytical assay for a novel anticancer candidate--ZMC1.

Lin H, Yu X, Eng OS, Buckley B, Kong AN, Bertino JR, Carpizo DR, Gounder MK.

Biomed Chromatogr. 2015 Nov;29(11):1708-14. doi: 10.1002/bmc.3483. Epub 2015 May 5.

19.

Methylthioadenosine phosphorylase (MTAP)-deficient T-cell ALL xenografts are sensitive to pralatrexate and 6-thioguanine alone and in combination.

Tedeschi PM, Kathari YK, Johnson-Farley N, Bertino JR.

Cancer Chemother Pharmacol. 2015 Jun;75(6):1247-52. doi: 10.1007/s00280-015-2747-2. Epub 2015 Apr 28.

20.

LFA-1-targeting Leukotoxin (LtxA; Leukothera®) causes lymphoma tumor regression in a humanized mouse model and requires caspase-8 and Fas to kill malignant lymphocytes.

DiFranco KM, Johnson-Farley N, Bertino JR, Elson D, Vega BA, Belinka BA Jr, Kachlany SC.

Leuk Res. 2015 Jun;39(6):649-56. doi: 10.1016/j.leukres.2015.03.010. Epub 2015 Mar 21.

21.

Darinaparsin inhibits prostate tumor-initiating cells and Du145 xenografts and is an inhibitor of hedgehog signaling.

Bansal N, Farley NJ, Wu L, Lewis J, Youssoufian H, Bertino JR.

Mol Cancer Ther. 2015 Jan;14(1):23-30. doi: 10.1158/1535-7163.MCT-13-1040. Epub 2014 Nov 7.

22.

ABT-199, a BH3 mimetic that specifically targets Bcl-2, enhances the antitumor activity of chemotherapy, bortezomib and JQ1 in "double hit" lymphoma cells.

Johnson-Farley N, Veliz J, Bhagavathi S, Bertino JR.

Leuk Lymphoma. 2015 Jul;56(7):2146-52. doi: 10.3109/10428194.2014.981172. Epub 2015 Jan 28.

PMID:
25373508
23.

Leucovorin rescue allows effective high-dose pralatrexate treatment and an increase in therapeutic index in mesothelioma xenografts.

Tedeschi PM, Kathari YK, Farooqi IN, Bertino JR.

Cancer Chemother Pharmacol. 2014 Nov;74(5):1029-32. doi: 10.1007/s00280-014-2580-z. Epub 2014 Sep 9.

24.

Sox9 mediates Notch1-induced mesenchymal features in lung adenocarcinoma.

Capaccione KM, Hong X, Morgan KM, Liu W, Bishop JM, Liu L, Markert E, Deen M, Minerowicz C, Bertino JR, Allen T, Pine SR.

Oncotarget. 2014 Jun 15;5(11):3636-50.

25.

6-thioguanine: a drug with unrealized potential for cancer therapy.

Munshi PN, Lubin M, Bertino JR.

Oncologist. 2014 Jul;19(7):760-5. doi: 10.1634/theoncologist.2014-0178. Epub 2014 Jun 13. Review.

26.

A novel peptide that inhibits E2F transcription and regresses prostate tumor xenografts.

Xie X, Bansal N, Shaik T, Kerrigan JE, Minko T, Garbuzenko O, Abali EE, Johnson-Farley N, Banerjee D, Scotto KW, Bertino JR.

Oncotarget. 2014 Feb 28;5(4):901-7.

27.

The metabolic demands of cancer cells are coupled to their size and protein synthesis rates.

Dolfi SC, Chan LL, Qiu J, Tedeschi PM, Bertino JR, Hirshfield KM, Oltvai ZN, Vazquez A.

Cancer Metab. 2013 Nov 7;1(1):20. doi: 10.1186/2049-3002-1-20.

28.

Contribution of serine, folate and glycine metabolism to the ATP, NADPH and purine requirements of cancer cells.

Tedeschi PM, Markert EK, Gounder M, Lin H, Dvorzhinski D, Dolfi SC, Chan LL, Qiu J, DiPaola RS, Hirshfield KM, Boros LG, Bertino JR, Oltvai ZN, Vazquez A.

Cell Death Dis. 2013 Oct 24;4:e877. doi: 10.1038/cddis.2013.393.

29.

Enrichment of human prostate cancer cells with tumor initiating properties in mouse and zebrafish xenografts by differential adhesion.

Bansal N, Davis S, Tereshchenko I, Budak-Alpdogan T, Zhong H, Stein MN, Kim IY, Dipaola RS, Bertino JR, Sabaawy HE.

Prostate. 2014 Feb;74(2):187-200. doi: 10.1002/pros.22740. Epub 2013 Oct 24.

30.

Antitumor and modeling studies of a penetratin-peptide that targets E2F-1 in small cell lung cancer.

Xie X, Kerrigan JE, Minko T, Garbuzenko O, Lee KC, Scarborough A, Abali EE, Budak-Alpdogan T, Johnson-Farley N, Banerjee D, Scotto KW, Bertino JR.

Cancer Biol Ther. 2013 Aug;14(8):742-51. doi: 10.4161/cbt.25184. Epub 2013 Jun 3.

31.

Enhanced degradation of dihydrofolate reductase through inhibition of NAD kinase by nicotinamide analogs.

Hsieh YC, Tedeschi P, Adebisi Lawal R, Banerjee D, Scotto K, Kerrigan JE, Lee KC, Johnson-Farley N, Bertino JR, Abali EE.

Mol Pharmacol. 2013 Feb;83(2):339-53. doi: 10.1124/mol.112.080218. Epub 2012 Nov 29.

32.

Overexpression of the mitochondrial folate and glycine-serine pathway: a new determinant of methotrexate selectivity in tumors.

Vazquez A, Tedeschi PM, Bertino JR.

Cancer Res. 2013 Jan 15;73(2):478-82. doi: 10.1158/0008-5472.CAN-12-3709. Epub 2012 Nov 7.

33.

Lack of expression of MTAP in uncommon T-cell lymphomas.

Bertino JR, Lubin M, Johnson-Farley N, Chan WC, Goodell L, Bhagavathi S.

Clin Lymphoma Myeloma Leuk. 2012 Oct;12(5):306-9. doi: 10.1016/j.clml.2012.07.001.

PMID:
23040436
34.

A second target of benzamide riboside: dihydrofolate reductase.

Roussel B, Johnson-Farley N, Kerrigan JE, Scotto KW, Banerjee D, Felczak K, Pankiewicz KW, Gounder M, Lin H, Abali EE, Bertino JR.

Cancer Biol Ther. 2012 Nov;13(13):1290-8. doi: 10.4161/cbt.21786. Epub 2012 Sep 6.

35.

Irradiated allogeneic cells enhance umbilical cord blood stem cell engraftment in immunodeficient mice.

Budak-Alpdogan T, Jeganathan G, Lee KC, Mrowiec ZR, Medina DJ, Todd D, Moore D, Bertino JR, Strair R.

Bone Marrow Transplant. 2012 Dec;47(12):1569-76. doi: 10.1038/bmt.2012.69. Epub 2012 May 21.

PMID:
22609880
36.

A validated HPLC assay for the determination of R-(-)-gossypol in human plasma and its application in clinical pharmacokinetic studies.

Lin H, Gounder MK, Bertino JR, Kong AN, DiPaola RS, Stein MN.

J Pharm Biomed Anal. 2012 Jul;66:371-5. doi: 10.1016/j.jpba.2012.03.029. Epub 2012 Mar 24.

37.

Plitidepsin (Aplidin) is a potent inhibitor of diffuse large cell and Burkitt lymphoma and is synergistic with rituximab.

Barboza NM, Medina DJ, Budak-Alpdogan T, Aracil M, Jimeno JM, Bertino JR, Banerjee D.

Cancer Biol Ther. 2012 Jan 15;13(2):114-22. doi: 10.4161/cbt.13.2.18876.

38.

Next generation sequencing of prostate cancer from a patient identifies a deficiency of methylthioadenosine phosphorylase, an exploitable tumor target.

Collins CC, Volik SV, Lapuk AV, Wang Y, Gout PW, Wu C, Xue H, Cheng H, Haegert A, Bell RH, Brahmbhatt S, Anderson S, Fazli L, Hurtado-Coll A, Rubin MA, Demichelis F, Beltran H, Hirst M, Marra M, Maher CA, Chinnaiyan AM, Gleave M, Bertino JR, Lubin M, Wang Y.

Mol Cancer Ther. 2012 Mar;11(3):775-83. doi: 10.1158/1535-7163.MCT-11-0826. Epub 2012 Jan 17.

39.

A validated bioanalytical HPLC method for pharmacokinetic evaluation of 2-deoxyglucose in human plasma.

Gounder MK, Lin H, Stein M, Goodin S, Bertino JR, Kong AN, DiPaola RS.

Biomed Chromatogr. 2012 May;26(5):650-4. doi: 10.1002/bmc.1710. Epub 2011 Sep 19.

40.

Are we getting closer to using methotrexate in an optimal manner?

Kamen BA, Bertino JR, Holcenberg JS, Bleyer WA.

J Clin Oncol. 2011 Sep 1;29(25):3493-4; author reply 3494-5. doi: 10.1200/JCO.2011.37.0312. Epub 2011 Aug 1. No abstract available.

PMID:
21810689
41.

Targeting tumors that lack methylthioadenosine phosphorylase (MTAP) activity: current strategies.

Bertino JR, Waud WR, Parker WB, Lubin M.

Cancer Biol Ther. 2011 Apr 1;11(7):627-32. Epub 2011 Apr 1. Review.

42.

Imaging colon cancer response following treatment with AZD1152: a preclinical analysis of [18F]fluoro-2-deoxyglucose and 3'-deoxy-3'-[18F]fluorothymidine imaging.

Moroz MA, Kochetkov T, Cai S, Wu J, Shamis M, Nair J, de Stanchina E, Serganova I, Schwartz GK, Banerjee D, Bertino JR, Blasberg RG.

Clin Cancer Res. 2011 Mar 1;17(5):1099-110. doi: 10.1158/1078-0432.CCR-10-1430. Epub 2011 Jan 18.

43.

Efficient generation of multipotent mesenchymal stem cells from umbilical cord blood in stroma-free liquid culture.

Peters R, Wolf MJ, van den Broek M, Nuvolone M, Dannenmann S, Stieger B, Rapold R, Konrad D, Rubin A, Bertino JR, Aguzzi A, Heikenwalder M, Knuth AK.

PLoS One. 2010 Dec 30;5(12):e15689. doi: 10.1371/journal.pone.0015689.

44.

MiR-24 tumor suppressor activity is regulated independent of p53 and through a target site polymorphism.

Mishra PJ, Song B, Mishra PJ, Wang Y, Humeniuk R, Banerjee D, Merlino G, Ju J, Bertino JR.

PLoS One. 2009 Dec 24;4(12):e8445. doi: 10.1371/journal.pone.0008445.

45.

Translational modulation of proteins expressed from bicistronic vectors.

Mishra PJ, Menon LG, Mishra PJ, Mayer-Kuckuk P, Bertino JR, Banerjee D.

Mol Imaging. 2009 Dec;8(6):305-18.

46.

Cancer research: from folate antagonism to molecular targets.

Bertino JR.

Best Pract Res Clin Haematol. 2009 Dec;22(4):577-82. doi: 10.1016/j.beha.2009.09.004. Review.

PMID:
19959110
47.

Heparin and suramin alter plitidepsin uptake via inhibition of GPCR coupled signaling.

Longo-Sorbello GS, Gao H, Mishra PJ, Kamen B, Soto A, Jimeno J, Aracil M, Paz de Paz MF, Bertino JR, Banerjee D.

J Chemother. 2009 Nov;21(5):550-7.

PMID:
19933047
48.

Accelerated R-COP: a pilot study for the treatment of advanced low grade lymphomas that has a high complete response rate.

Levitt MJ, Gharibo M, Strair R, Schaar D, Rubin A, Bertino JR.

J Chemother. 2009 Aug;21(4):434-8.

PMID:
19622463
49.

Species-specific differences in translational regulation of dihydrofolate reductase.

Hsieh YC, Skacel NE, Bansal N, Scotto KW, Banerjee D, Bertino JR, Abali EE.

Mol Pharmacol. 2009 Oct;76(4):723-33. doi: 10.1124/mol.109.055772. Epub 2009 Jul 1.

50.

Chemoprotection by transfer of resistance genes.

Budak-Alpdogan T, Bertino JR.

Methods Mol Biol. 2009;542:661-704. doi: 10.1007/978-1-59745-561-9_34.

PMID:
19565927

Supplemental Content

Loading ...
Support Center